Last Updated: November 16, 2026

Vadadustat - Generic Drug Details

« Back to Dashboard


What are the generic sources for vadadustat and what is the scope of freedom to operate?

Vadadustat is the generic ingredient in one branded drug marketed by Akebia and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for vadadustat
International Patents:268
US Patents:14
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 32
Patent Applications: 415
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for vadadustat
What excipients (inactive ingredients) are in vadadustat?vadadustat excipients list
DailyMed Link:vadadustat at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for vadadustat
Generic Entry Date for vadadustat*:
Constraining patent/regulatory exclusivity:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vadadustat

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bentley J. BobrowPHASE2
Akebia Therapeutics Inc.PHASE2
Akebia TherapeuticsPHASE3

See all vadadustat clinical trials

US Patents and Regulatory Information for vadadustat

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akebia VAFSEO vadadustat TABLET;ORAL 215192-003 Mar 27, 2024 DISCN Yes No 9,701,636 ⤷  Start Trial Y Y ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-001 Mar 27, 2024 RX Yes No 11,324,734 ⤷  Start Trial Y ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-003 Mar 27, 2024 DISCN Yes No 9,987,262 ⤷  Start Trial ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-001 Mar 27, 2024 RX Yes No 9,701,636 ⤷  Start Trial Y Y ⤷  Start Trial
Akebia VAFSEO vadadustat TABLET;ORAL 215192-002 Mar 27, 2024 RX Yes No 7,811,595 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for vadadustat

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Akebia Europe Limited Vafseo vadadustat EMEA/H/C/005131Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. Authorised no no no 2023-04-24
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Supplementary Protection Certificates for vadadustat

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3007695 C202430024 Spain ⤷  Start Trial PRODUCT NAME: VADADUSTAT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1725; DATE OF AUTHORISATION: 20230424; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1725; DATE OF FIRST AUTHORISATION IN EEA: 20230424
3007695 CR 2024 00026 Denmark ⤷  Start Trial PRODUCT NAME: VADADUSTAT; REG. NO/DATE: EU/1/23/1725 20230425
3007695 PA2024521 Lithuania ⤷  Start Trial PRODUCT NAME: VADADUSTATAS; REGISTRATION NO/DATE: EU/1/23/1725 20230424
3007695 202440023 Slovenia ⤷  Start Trial PRODUCT NAME: VADADUSTAT; NATIONAL AUTHORISATION NUMBER: EU/1/23/1725; DATE OF NATIONAL AUTHORISATION: 20230424; AUTHORITY FOR NATIONAL AUTHORISATION: EU
3007695 122024000039 Germany ⤷  Start Trial PRODUCT NAME: VADADUSTAT (VAFSEO); REGISTRATION NO/DATE: EU/1/23/1725 20230424
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Vadadustat Market Dynamics and Financial Trajectory

Last updated: September 21, 2026

Vadadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor marketed as Vafseo by Akebia Therapeutics. The U.S. Food and Drug Administration approved it in March 2024 for anemia caused by chronic kidney disease in adults who have been receiving dialysis for at least three months. Its commercial opportunity is concentrated in the dialysis anemia market, where it competes with erythropoiesis-stimulating agents, iron therapy, and AstraZeneca’s daprodustat. Akebia’s financial trajectory depends on converting dialysis-center adoption into recurring U.S. product revenue while maintaining royalty and license income from international markets.

What is vadadustat and which patients can receive Vafseo?

Vadadustat is an oral HIF-PHI that stabilizes hypoxia-inducible factor and increases endogenous erythropoietin production. Vafseo is approved in the United States for adults with anemia due to chronic kidney disease who have been on dialysis for at least three months.[1]

The U.S. label does not provide a broad non-dialysis indication. That limitation materially reduces the addressable U.S. population compared with products that can be used across dialysis and non-dialysis CKD populations.

Attribute Vadadustat
Brand Vafseo
Developer Akebia Therapeutics
Drug class HIF prolyl hydroxylase inhibitor
U.S. approval March 27, 2024
U.S. indication CKD anemia in adults on dialysis for at least three months
Route Oral
Principal U.S. competitor Daprodustat, marketed as Jesduvroq
Established treatment alternatives Epoetin alfa, darbepoetin alfa, intravenous iron, oral iron
Primary commercial channel Dialysis providers and specialty distribution

The FDA required a boxed warning for increased risks of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access. The safety profile makes payer coverage, dialysis-provider protocols, and physician confidence central to adoption.[1]

How large is the vadadustat market?

The initial U.S. market is the dialysis anemia segment rather than the entire CKD anemia population. The United States has roughly 800,000 people with end-stage kidney disease, with most receiving maintenance dialysis. Not all patients are candidates for an oral HIF-PHI, and existing ESA therapy is deeply embedded in dialysis-center workflows.[2]

Vadadustat’s commercial opportunity has four components:

  1. Conversion of patients from injectable ESAs.
  2. Use in patients with suboptimal ESA response.
  3. Use where oral administration reduces injection burden.
  4. International sales and royalties from markets where Vafseo has broader approval.

The market is structurally concentrated. Large dialysis organizations, including Fresenius Kidney Care and DaVita, influence formulary placement and treatment protocols. A drug that receives national or regional dialysis-organization adoption can scale faster than a conventional specialty product, but it may face substantial price negotiation.

How does Vafseo compare with Jesduvroq?

Factor Vafseo Jesduvroq
Active ingredient Vadadustat Daprodustat
Manufacturer Akebia Therapeutics GlaxoSmithKline
U.S. approval 2024 2023
U.S. dialysis population Adults on dialysis at least three months Adults on dialysis at least four months
Oral administration Yes Yes
Non-dialysis U.S. use Not approved Approved in non-dialysis and dialysis settings under its label
Commercial scale Launch-stage Established commercial infrastructure through GSK
Key risk Limited U.S. label and smaller commercial organization Class-wide cardiovascular and thrombotic safety concerns

The U.S. competitive position favors daprodustat on label breadth and corporate scale. Vadadustat has a potentially important advantage in international development, prior clinical experience, and an established Japanese commercial history.

When did vadadustat lose exclusivity, and what patents protect Vafseo?

Vadadustat’s market protection combines patents, regulatory exclusivity, formulation protection, and commercial agreements. The U.S. product is sufficiently new that regulatory exclusivity is less important than the remaining patent term and the scope of any Orange Book-listed claims.

The FDA approved Vafseo in 2024, creating five years of new chemical entity exclusivity if the product qualified for that designation. The FDA approval was for a specific dialysis population, and the approved indication is also relevant to future abbreviated new drug application litigation.[1]

Potential patent categories include:

  • Composition-of-matter claims covering vadadustat.
  • Pharmaceutical compositions and solid forms.
  • Methods of treating CKD-associated anemia.
  • Dosing regimens for dialysis patients.
  • Manufacturing and purification processes.
  • Combination or coadministration methods involving iron or dialysis treatment.

Akebia’s U.S. patent portfolio also reflects the company’s earlier development of vadadustat under the name AKB-6548. Public patent records identify composition and method-of-use filings associated with Akebia and earlier development collaborators, but the commercial relevance of each patent depends on Orange Book listing, claim scope, terminal disclaimers, prosecution history, and enforceability.

What is the Orange Book status of Vafseo?

Vafseo became eligible for Orange Book listing following FDA approval. Orange Book protection may include patents covering the active ingredient, drug product, formulation, or approved method of use.[3]

For generic-entry analysis, the critical questions are:

Issue Commercial significance
Listed composition patent Can support a broad Paragraph IV challenge
Method-of-use patent May permit skinny-label strategies
Formulation patent Can delay generic substitution if the formulation is necessary
Patent expiration Determines the earliest likely launch date
Regulatory exclusivity May block approval independently of patents
Label scope Defines what generic applicants must carve out

A generic applicant seeking approval before listed patent expiration could file a Paragraph IV certification. Akebia would then have 45 days to initiate patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman Act.[4]

No broad U.S. generic market is expected immediately after launch because Vafseo’s approval is recent and the product’s commercial patents and regulatory exclusivity remain central barriers.

What is the FDA regulatory status of vadadustat?

The FDA rejected vadadustat in 2022 because of concerns about cardiovascular safety and the benefit-risk profile in non-dialysis patients. Akebia later resubmitted the application with a narrower dialysis indication. The FDA approved Vafseo in 2024 for adults on dialysis for at least three months.[1,5]

The regulatory history affects market dynamics in three ways:

  • The narrower label reduces the initial U.S. patient pool.
  • The approval demonstrates that the FDA accepted a dialysis-specific benefit-risk profile.
  • The prior complete response letter increases attention on postmarketing safety and real-world cardiovascular outcomes.

Vafseo’s class carries safety restrictions that could limit use in patients with uncontrolled hypertension, recent cardiovascular events, or high thrombotic risk. Dialysis providers are likely to use protocols that prioritize hemoglobin monitoring and vascular-access safety.

Which companies are challenging vadadustat?

No major publicly disclosed U.S. Paragraph IV litigation campaign had materially altered Vafseo’s commercial position immediately following approval. The more important competitive challenge comes from marketed treatment alternatives rather than litigation.

Competitive threats

  • GSK’s daprodustat competes directly as another oral HIF-PHI.
  • Biosimilar epoetin products compete on price and clinical familiarity.
  • Originator and biosimilar ESAs remain integrated into dialysis reimbursement.
  • Intravenous iron can reduce ESA requirements.
  • Emerging HIF-PHI products may enter markets outside the United States.

Biosimilar risk is indirect rather than molecule-specific. Vadadustat is a small molecule, so it faces conventional generic substitution rather than a biologic biosimilar pathway. The relevant FDA pathway is an ANDA, not a 351(k) biosimilar application.

What formulations and method-of-use patents protect vadadustat?

The strongest commercial protection would come from claims that prevent substitution with a chemically distinct but therapeutically equivalent product. Composition claims are generally more valuable than narrow dosing claims because they cover multiple formulations and indications.

Formulation and method-of-use protection may cover:

  • Oral tablets containing vadadustat.
  • Specific dose strengths and dosing schedules.
  • Treatment of anemia in dialysis patients.
  • Hemoglobin maintenance or correction protocols.
  • Use in patients receiving concomitant iron.
  • Dose adjustment based on hemoglobin response.

Method-of-use patents may be less durable against generics if a generic applicant can carve out the patented indication while retaining approval for an unpatented use. Product and formulation claims are harder to avoid through label language alone.

What licensing deals support vadadustat revenue?

Akebia has relied on regional partnerships to commercialize vadadustat outside the United States.

Partner or market Commercial role
Mitsubishi Tanabe Pharma Japanese development and commercialization relationship
CSL Vifor European commercial relationship and access to nephrology channels
Akebia U.S. development, regulatory approval, and Vafseo commercialization

Vadadustat received Japanese approval before U.S. approval and has generated international commercial experience. European regulatory approval expanded the product’s geographic reach, although local labeling and reimbursement determine actual sales.[6,7]

International licensing produces lower-cost revenue than a fully owned launch because partners fund local commercialization and pay royalties, milestones, or other contractual consideration. The tradeoff is lower gross revenue and reduced control over pricing and market access.

What is Akebia’s financial trajectory after Vafseo approval?

Akebia’s financial profile has historically depended on three revenue sources:

  1. Auryxia product sales in the United States.
  2. Vadadustat royalties, milestones, and international economics.
  3. Financing and strategic transactions used to fund development and commercialization.

Vafseo changes the trajectory by adding a wholly owned U.S. commercial product. The launch also increases operating expenses because Akebia must fund sales, medical affairs, market access, pharmacovigilance, manufacturing inventory, and postmarketing commitments.

Financial driver Near-term effect
U.S. Vafseo launch Raises revenue potential but increases selling expense
Auryxia sales Provides an existing commercial base
International vadadustat royalties Adds recurring, lower-margin revenue
Dialysis-provider contracting May limit net price and delay revenue recognition
Manufacturing scale-up Can improve gross margin after launch
Postmarketing studies Increase research and regulatory costs
Patent protection Supports pricing and reduces immediate generic erosion

Akebia’s key financial transition is from a development-stage biotechnology model toward a commercial specialty-pharmaceutical model. Revenue growth depends less on regulatory milestones and more on prescription volume, dialysis-account penetration, gross-to-net deductions, and repeat use.

What revenue exposure does vadadustat create?

Vadadustat creates material upside but also concentration risk. A narrow U.S. dialysis label limits the maximum near-term revenue opportunity. The product must displace entrenched injectable therapies in a market where treatment is often managed through bundled dialysis economics rather than conventional retail prescriptions.

The main commercial variables are:

  • Number of dialysis patients converted from ESAs.
  • Net price after discounts and rebates.
  • Adoption by large dialysis organizations.
  • Average treatment duration.
  • Hospital and nephrology referral patterns.
  • Manufacturing cost per tablet.
  • International royalty rates.
  • Speed of payer coverage after launch.

A successful launch could materially increase Akebia’s recurring product revenue. A slow conversion rate would leave the company dependent on Auryxia and partner-derived vadadustat income.

What generic launch risks exist for Vafseo?

Generic launch risk is limited in the near term by the product’s recent FDA approval, patent protection, and regulatory exclusivity. The risk increases as composition patents approach expiration and as generic manufacturers assess the commercial size of the dialysis market.

Likely launch scenarios

Scenario Timing logic Market effect
Early settlement entry Patent settlement permits launch before expiry Gradual share erosion
Patent litigation victory Listed patents remain enforceable Delayed generic competition
Patent invalidation Court cancels key claims Rapid price pressure
Skinny-label entry Generic carves out protected use Partial competition
Post-expiry entry Entry follows patent and exclusivity loss Broad substitution and margin decline

The dialysis market is less exposed to ordinary retail substitution because providers and payers may impose formulary controls. Even so, generic entry would pressure both list price and net price.

How strong is the vadadustat patent estate?

Vadadustat has a commercially relevant estate because it combines early composition development with later product-specific and use-specific filings. Its strength depends on whether the broadest surviving claims cover the approved Vafseo product and dialysis indication.

The estate is stronger if:

  • A composition patent remains valid after regulatory exclusivity ends.
  • Orange Book-listed claims cover the marketed tablet.
  • Method-of-use claims cover the only approved use.
  • Formulation patents prevent practical substitution.
  • Patent term adjustment or patent term extension adds meaningful time.
  • Prosecution history supports a broad claim construction.

The estate is weaker if protection relies mainly on narrow methods that can be carved out, if composition claims expire relatively soon, or if multiple prior-art references create invalidity risk.

What patent litigation affects vadadustat?

The principal litigation risk is future Hatch-Waxman litigation triggered by an ANDA with a Paragraph IV certification. A lawsuit would focus on infringement, validity, and enforceability of the listed patents. The commercial outcome could include a 30-month stay, an agreed launch date, a license, or a court decision allowing early generic entry.[4]

No settlement agreement creating a publicly established early generic launch date had become the defining feature of Vafseo’s commercial outlook following FDA approval. The more immediate issue is whether Akebia can establish sufficient adoption before challengers create pricing pressure.

How does vadadustat compare with competing CKD anemia drugs?

Product class Administration Main advantage Main commercial limitation
Vadadustat Oral Avoids injection and has international experience U.S. label limited to established dialysis patients
Daprodustat Oral Broader U.S. label and GSK infrastructure Same class-wide cardiovascular concerns
Epoetin alfa Injection Long clinical history and broad dialysis use Injection burden and ESA safety concerns
Darbepoetin alfa Injection Longer dosing interval Higher cost and injection administration
IV iron Intravenous Treats iron deficiency and can reduce ESA use Does not replace all erythropoietic therapy
Biosimilar ESAs Injection Lower acquisition cost Same administration and clinical workflow

Key Takeaways

  • Vadadustat is marketed in the United States as Vafseo by Akebia Therapeutics.
  • FDA approval covers adults with CKD anemia who have received dialysis for at least three months.
  • The U.S. opportunity is meaningful but narrower than the total CKD anemia market.
  • Daprodustat is the principal direct U.S. oral competitor.
  • ESAs, biosimilar ESAs, and intravenous iron remain the largest practical alternatives.
  • Akebia’s financial trajectory depends on U.S. dialysis-center adoption, net pricing, and partner royalties.
  • Vafseo has recent regulatory protection and a developing patent estate, limiting immediate generic risk.
  • Future Paragraph IV litigation is the main U.S. patent threat.
  • International partnerships provide geographic reach but reduce Akebia’s direct revenue capture.
  • The commercial outcome will depend on whether oral convenience can overcome entrenched ESA reimbursement and dialysis-provider protocols.

FAQs

Is vadadustat approved for non-dialysis CKD patients in the United States?

No. Vafseo’s U.S. label is limited to adults with CKD anemia who have been on dialysis for at least three months.[1]

Does vadadustat have a biosimilar competitor?

No. Vadadustat is a small molecule. Future competitors would generally seek approval through the ANDA generic pathway rather than the FDA biosimilar pathway.

Who manufactures Vafseo?

Akebia Therapeutics owns the U.S. commercialization rights and markets Vafseo in the United States. International commercialization is supported by regional partners.

Is Vafseo more expensive than epoetin?

The effective cost depends on payer rebates, dialysis-provider contracts, dosing, and the cost of administration. Oral administration may reduce injection-related burden, but the drug must compete with established bundled ESA economics.

What is the biggest investment risk for Akebia from vadadustat?

The largest risk is slower-than-expected conversion of dialysis patients from established ESAs. A narrow label, cardiovascular safety warnings, contracting pressure, and competition from daprodustat could limit revenue growth despite FDA approval.

References

  1. U.S. Food and Drug Administration. (2024). Vafseo (vadadustat) prescribing information.
  2. United States Renal Data System. (2024). 2024 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
  4. U.S. Code, 21 U.S.C. § 355(j). Hatch-Waxman abbreviated new drug application provisions.
  5. Akebia Therapeutics, Inc. (2022). Form 10-K and announcement regarding the FDA complete response letter for vadadustat.
  6. European Medicines Agency. (2023). Vafseo: European public assessment report.
  7. Akebia Therapeutics, Inc. (2024). Annual report and corporate disclosures regarding Vafseo, Auryxia, and international commercialization.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.